Skip to main content

Table 1 Summary of anti-PfCyRPA mAbs characterization

From: Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA

mAb

Immunization

ELISA

Western blotting analysis

IFA

GIA

Epitope group

G-CyRPA

N-CyRPA

G-CyRPA

N-CyRPA

P. falc. 3D7

P. falc. 3D7

P. falc. 3D7

SB1.5

G-CyRPA

+

+

+

+

+

−

Partial

nd

SB1.6

G-CyRPA

+

+

+

+

+

+

Yes

F

SB2.1

N-CyRPA

+

+

+

+

+

+

Yes

F

SB2.2

N-CyRPA

+

+

−

−

−

−

Partial

nd

SB2.3

N-CyRPA

+

+

+

+

+

+

Yes

F

SB2.4

N-CyRPA

+

+

−

−

+

+

No

nd

SB2.5

N-CyRPA

+

+

+

+

+

+

Partial

A

SB3.3

G-CyRPA

+

+

+

+

+

+

Yes

F

SB3.7

G-CyRPA

+

+

+

+

+

+

Partial

B

SB3.8

G-CyRPA

+

−

−

−

+

+

No

nd

SB3.9

G-CyRPA

+

+

+

+

+

+

No

E

  1. Anti-PfCyRPA mAbs were characterized by ELISA (+, OD value higher than control anti-6xHis mAb HIS-6/9; −, OD value ≤ control mAb), western blotting analyses (+, staining; −, no staining; cf. Fig. 3), immunofluorescence assays (+, staining; −, no staining), growth inhibition assays (yes, GIA ≥40 %; no, GIA ≤20 %) and categorized into distinct epitope groups by epitope mapping experiments (cf. Fig. 8). G-CyRPA designates recombinant glycosylated PfCyRPA whereas N-CyRPA designates non-glycosylated recombinant PfCyRPA